Gland Pharma (NSE:GLAND) Accounts Payable: ₹8,339 Mil (As of Mar. 2026)


NSE:GLAND Gland Pharma Ltd NSE:GLAND
84 GF Score
Price ₹2,495.80
GF Value ₹2,134.88
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Gland Pharma Accounts Payable?

Gland Pharma NSE:GLAND -2.13% 84 Accounts Payable is ₹8,339 Mil as of Mar. 2026. GuruFocus rates NSE:GLAND with a GF Score™ of 84/100 and a GF Value™ of ₹2,134.88 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Gland Pharma's Accounts Payable for the quarter that ended in Mar. 2026 was ₹8,339 Mil.

Gland Pharma's quarterly Accounts Payable declined from Sep. 2025 (₹9,236 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹8,339 Mil).

Gland Pharma's annual Accounts Payable increased from Mar. 2024 (₹7,677 Mil) to Mar. 2025 (₹8,204 Mil) and increased from Mar. 2025 (₹8,204 Mil) to Mar. 2026 (₹8,339 Mil).

Gland Pharma Accounts Payable Historical Data

* Premium members only.

The historical data trend for Gland Pharma's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gland Pharma Accounts Payable Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Accounts Payable
Get a 7-Day Free Trial Premium Member Only 4,628.50 5,873.50 7,677.49 8,204.10 8,338.74

Gland Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,204.10 0.00 9,235.57 0.00 8,338.74
NSE:GLAND
84GF Score
Gland Pharma Ltd NSE:GLAND
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gland Pharma Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ₹8,339 Mil mean?
Gland Pharma (NSE:GLAND) has a Accounts Payable of ₹8,339 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Gland Pharma and its competitors.
Is Gland Pharma's Accounts Payable too high?
Gland Pharma's current Accounts Payable is ₹8,339 Mil. Overall, Gland Pharma has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Accounts Payable compare to ZTS and UTHR?
Gland Pharma's Accounts Payable of ₹8,339 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Gland Pharma and its competitors. Gland Pharma's current Accounts Payable is ₹8,339 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,134.88, compared to a current price of ₹2,495.80 — trading 16.9% above its estimated fair value. The current Accounts Payable is ₹8,339 Mil. Gland Pharma's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Accounts Payable is ₹8,339 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gland Pharma (NSE:GLAND) Overvalued in 2026?

Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued. The current stock price of ₹2,495.80 is trading 16.9% above its estimated GF Value™ of ₹2,134.88. GuruFocus considers Gland Pharma to be Modestly Overvalued.

Key valuation signals for NSE:GLAND:

  • Accounts Payable: ₹8,339 Mil
  • GF Value™: ₹2,134.88 vs. price of ₹2,495.80 (16.9% above fair value)
  • GF Score™: 84/100 with 7 warning signs

No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gland Pharma Business Description

Other Exchanges 543245:India
Address TSIIC, Phase - IV, Plot No. 11 and 84, Pashamylaram (V), Patancheru M, Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
84GF Score

Get the complete analysis for NSE:GLAND

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,495.80
Price
₹2,134.88
GF Value